138 related articles for article (PubMed ID: 38748049)
1. Association between PET-CT accumulation in the hypothalamic/pituitary regions and neuron-specific enolase/primary tumor in limited-stage small cell lung cancer: a case-controlled retrospective study.
Okada Y; Zama T; Itonaga T; Mikami R; Okubo M; Sugahara S; Nakai M; Abe K; Yoshimura M; Saito K
EJNMMI Rep; 2024 Feb; 8(1):4. PubMed ID: 38748049
[TBL] [Abstract][Full Text] [Related]
2. Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.
Shi P; Meng X; Ni M; Sun X; Xing L; Yu J
Oncol Lett; 2015 Nov; 10(5):3123-3128. PubMed ID: 26722299
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
7. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
8. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by
Ottestad AL; Johansen H; Halvorsen TO; Dai HY; Wahl SGF; Emdal EF; Grønberg BH
BMC Cancer; 2023 Jul; 23(1):646. PubMed ID: 37434111
[TBL] [Abstract][Full Text] [Related]
9. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
11. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
[No Abstract] [Full Text] [Related]
12. Clinical Significance of Quantitative FDG PET/CT Parameters in Non-Small Cell Lung Cancer Patients.
Behgam Shadmehr M; Khosravi A; Abbasi Dezfouli A; Bakhshayesh-Karam M; Jamaati H; Doroudinia A; Mohaghegh SM; Mehrian P; Emami H; Dorudinia A
Tanaffos; 2020 Jul; 19(3):186-194. PubMed ID: 33815538
[TBL] [Abstract][Full Text] [Related]
13. The value on SUV-derived parameters assessed on
Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
[TBL] [Abstract][Full Text] [Related]
14. Risk analysis in peripheral clinical T1 non-small cell lung cancer correlations between tumor-to-blood standardized uptake ratio on
Li XF; Shi YM; Niu R; Shao XN; Wang JF; Shao XL; Zhang FF; Wang YT
Quant Imaging Med Surg; 2022 Jan; 12(1):159-171. PubMed ID: 34993068
[TBL] [Abstract][Full Text] [Related]
15. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
16. The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer.
Eryilmaz A; Cengiz A; Basal Y; Meteoglu I; Omurlu IK; Yurekli Y
J Cancer Res Ther; 2018; 14(5):994-998. PubMed ID: 30197337
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of
Ren J; Fu Z; Zhao Y
Front Oncol; 2023; 13():1099290. PubMed ID: 37035169
[TBL] [Abstract][Full Text] [Related]
19.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
[Next] [New Search]